蒽环类药物相关心脏毒性早期生物标志物研究进展

doi:10.11904/j.issn.1002-3070.2023.06.007

Abstract

Abstract: Anthracyclines are one of the widely used anti-tumor drugs in clinical practice.Its dose-related cardiotoxicity can affect the quality of life and survival rate of cancer patients,so early identification of anthracycline related cardiotoxicity is particularly important.This article provides a review of the research progress on early biomarkers of anthracycline related cardiotoxicity.

Key words: Anthracycline, Cardiotoxicity, Biomarker, Research progress

CLC Number:

R730.53

LU Yajie, WANG Lihong. Advances in early biomarkers of anthracyclines related to cardiotoxicity[J]. Journal of Practical Oncology, 2023, 37(6): 496-501.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.06.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I6/496

References

1 Sobczuk P,Czerwińska M,Kleibert M,et al.Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications[J].Heart Fail Rev,2022,27(1):295-319.
2 Simões R,Silva LM,Cruz A,et al.Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy:A narrative review[J].Biomed Pharmacother,2018,107:989-996.
3 Newby LK,Rodriguez I,Finkle J,et al.Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity:An educational collaboration among the cardiac safety research consortium,the duke clinical research institute,and the us food and drug administration[J].Am Heart J,2011,162(1):64-73.
4 Meessen J,Cardinale D,Ciceri F,et al.Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines:The icos-one trial[J].ESC Heart Fail,2020,7(4):1452-1466.
5 Demissei BG,Hubbard RA,Zhang L,et al.Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction[J].J Am Heart Assoc,2020,9(2):e014708.
6 Kirkham AA,Pituskin E,Thompson RB,et al.Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity:A secondary analysis of the manticore trial[J].Eur Heart J Cardiovasc Pharmacother,2022,8(2):130-139.
7 Kapoun AM,Liang F,O′Young G,et al.B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts:Fibrosis,myofibroblast conversion,proliferation,and inflammation[J].Circ Res,2004,94(4):453-461.
8 Ito T,Yoshimura M,Nakamura S,et al.Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes[J].Circulation,2003,107(6):807-810.
9 Xiao H,Wang X,Li S,et al.Advances in biomarkers for detecting early cancer treatment-related cardiac dysfunction[J].Front Cardiovasc Med,2021,8:753313.
10 Skovgaard D,Hasbak P,Kjaer A.BNP predicts chemotherapy-related cardiotoxicity and death:Comparison with gated equilibrium radionuclide ventriculography[J].PLoS One,2014,9(5):e96736.
11 Leerink JM,Verkleij SJ,Feijen EAM,et al.Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors:A systematic review[J].Heart,2019,105(3):210-216.
12 Tonry C,Russell-Hallinan A,McCune C,et al.Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction[J].Cardiovasc Res,2023,119(3):710-728.
13 Ndrepepa G.Myeloperoxidase-A bridge linking inflammation and oxidative stress with cardiovascular disease[J].Clin Chim Acta,2019,493:36-51.
14 Nettersheim FS,Schlüter JD,Kreuzberg W,et al.Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy[J].Basic Res Cardiol,2023,118(1):36-54.
15 Todorova VK,Hsu PC,Wei JY,et al.Biomarkers of inflammation,hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients[J].Am J Cancer Res,2020,10(9):2933-2945.
16 Badimon L,Peña E,Arderiu G,et al.C-reactive protein in atherothrombosis and angiogenesis[J].Front Immunol,2018,9:430-436.
17 Venugopal SK,Devaraj S,Jialal I.C-reactive protein decreases prostacyclin release from human aortic endothelial cells[J].Circulation,2003,108(14):1676-1678.
18 Venugopal SK,Devaraj S,Yuhanna I,et al.Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells[J].Circulation,2002,106(12):1439-1441.
19 Kuppa A,Tripathi H,Al-Darraji A,et al.C-reactive protein levels and risk of cardiovascular diseases:A two-sample bidirectional mendelian randomization study[J].Int J Mol Sci,2023,24(11):9129-9149.
20 Hasan D,Ismail Y,Al Tibi A,et al.Serum biomarkers for chemotherapy cardiotoxicity risk detection of breast cancer patients[J].Asian Pac J Cancer Prev,2021,22(10):3355-3363.
21 Pusceddu I,Dieplinger B,Mueller T.ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans[J].Clin Chim Acta,2019,495:493-500.
22 Seki K,Sanada S,Kudinova AY,et al.Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling[J].Circ Heart Fail,2009,2(6):684-691.
23 Sanada S,Hakuno D,Higgins LJ,et al.IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system[J].J Clin Invest,2007,117(6):1538-1549.
24 Veeraveedu PT,Sanada S,Okuda K,et al.Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress[J].Biochem Pharmacol,2017,138:73-80.
25 Huang G,Zhai J,Huang X,et al.Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy[J].Medicine(Baltimore),2018,97(38):e12447.
26 Chen C,Li J,Rossi L,et al.Prognostic role of serum soluble ST2 of advanced breast cancer patients:A retrospective cohort study[J].Transl Cancer Res,2023,12(8):2128-2137.
27 Joolharzadeh P,Rodriguez M,Zaghlol R,et al.Recent advances in serum biomarkers for risk stratification and patient management in cardio-oncology[J].Curr Cardiol Rep,2023,25(3):133-146.
28 Xu J,Kimball TR,Lorenz JN,et al.GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation[J].Circ Res,2006,98(3):342-350.
29 Kempf T,Eden M,Strelau J,et al.The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury[J].Circ Res,2006,98(3):351-360.
30 Dean M,Kim MJ,Dimauro S,et al.Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy-a prospective analysis[J].Cardiooncology,2023,9(1):23-32.
31 Putt M,Hahn VS,Januzzi JL,et al.Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin,taxanes,and trastuzumab[J].Clin Chem,2015,61(9):1164-1172.
32 Witman N,Zhou C,Häneke T,et al.Placental growth factor exerts a dual function for cardiomyogenesis and vasculogenesis during heart development[J].Nat Commun,2023,14(1):5435-5451.
33 Takeda Y,Uemura S,Iwama H,et al.Treatment with recombinant placental growth factor(PIGF)enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction[J].Circ J,2009,73(9):1674-1682.
34 Zhang Y,Cao C,Xin J,et al.Treatment with placental growth factor attenuates myocardial ischemia/reperfusion injury[J].PLoS One,2018,13(9):e0202772.
35 Accornero F,van Berlo JH,Benard MJ,et al.Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism[J].Circ Res,2011,109(3):272-280.
36 Kaya MK,Demir T,Bulut H,et al.Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization[J].Clin Exp Ophthalmol,2015,43(5):449-457.
37 Sharma UC,Pokharel S,van Brakel TJ,et al.Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J].Circulation,2004,110(19):3121-3128.
38 Al-Salam S,Kandhan K,Sudhadevi M,et al.Early doxorubicin myocardial injury:Inflammatory,oxidative stress,and apoptotic role of galectin-3[J].Int J Mol Sci,2022,23(20):12479.
39 Ky B,Putt M,Sawaya H,et al.Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin,taxanes,and trastuzumab[J].J Am Coll Cardiol,2014,63(8):809-816.
40 Vishnoi A,Rani S.miRNA biogenesis and regulation of diseases:An updated overview[J].Methods Mol Biol,2023,2595:1-12.
41 Frères P,Bouznad N,Servais L,et al.Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients[J].BMC Cancer,2018,18(1):102-110.
42 Lakhani HV,Pillai SS,Zehra M,et al.Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer[J].Sci Rep,2021,11(1):7954-7964.
43 Zhu JN,Fu YH,Hu ZQ,et al.Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity[J].Sci Rep,2017,7(1):11879.
44 Jing X,Yang J,Jiang L,et al.MicroRNA-29b regulates the mitochondria-dependent apoptotic pathway by targeting bax in doxorubicin cardiotoxicity[J].Cell Physiol Biochem,2018,48(2):692-704.
45 Han L,Ju A,Guo Y,et al.miR-126 inhibits vascular endothelial cell apoptosis in rats with coronary heart disease through PI3K/Akt pathway[J].Minerva Surg,2023,78(1):96-97.
46 Oatmen KE,Toro-Salazar OH,Hauser K,et al.Identification of a novel microRNA profile in pediatric patients with cancer treated with anthracycline chemotherapy[J].Am J Physiol Heart Circ Physiol,2018,315(5):1443-1452.
47 Horacek JM,Jebavy L,Vasatova M,et al.Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia[J].Bratisl Lek Listy,2013,114(12):708-710.
48 Finkelman BS,Putt M,Wang T,et al.Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer[J].J Am Coll Cardiol,2017,70(2):152-162.
49 Yu LR,Cao Z,Makhoul I,et al.Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients[J].Exp Biol Med(Maywood),2018,243(3):248-255.
50 Tian C,Yang Y,Bai B,et al.Potential of exosomes as diagnostic biomarkers and therapeutic carriers for doxorubicin-induced cardiotoxicity[J].Int J Biol Sci,2021,17(5):1328-1338.

[1]	LU Jiaoyang, CHANG Jin. Research progress in biomarkers for multiple myeloma [J]. Journal of Practical Oncology, 2023, 37(1): 87-91.
[2]	LI Hao, TENG Lichen. Research status of exosomal circular RNA in prostate cancer [J]. Journal of Practical Oncology, 2023, 37(1): 92-96.
[3]	WU Ruiyue, ZHU Kaili, YANG Jingru, LING Xiaoling. Clinical research progress of breast cancer with low HER2 expression [J]. Journal of Practical Oncology, 2022, 36(6): 570-575.
[4]	CHEN Junhui, LIU Siyu, HE Changjun. Research progress of RUNX1 in lung cancer [J]. Journal of Practical Oncology, 2022, 36(6): 576-579.
[5]	ZHAO Yaru, WU Yun. Research status of common biomarkers and corresponding targeted therapy for gastric cancer [J]. Journal of Practical Oncology, 2022, 36(5): 483-488.
[6]	LIU Jia, YANG Daokun, WANG Yanping, CHEN Baoxin, WANG Xinwei, SHEN Jiao. Research status of biomarkers related to the efficacy of PD-1 inhibitors in the treatment of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(4): 374-380.
[7]	WANG Siran, HU Weiping. Research progress of immune checkpoint inhibitors in the treatment of oral squamous cell carcinoma [J]. Journal of Practical Oncology, 2022, 36(1): 79-83.
[8]	ZHAO Haoran, LI Man, ZHANG Yubao. Research progress of hepatocellular carcinoma-related RNA binding protein [J]. Journal of Practical Oncology, 2021, 35(6): 576-579.
[9]	LU Junrong, WANG Huiwen, HE Dongfeng. Significance of high expression of SALL4 in clinicopathological and prognostic judgment of esophageal squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(5): 420-425.
[10]	WANG Ye, SHANG Naijian. Application progress of radiomics in the diagnosis and treatment of non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(5): 485-488.
[11]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.
[12]	FENG Yuxin,ZHU Chunrong. Research progress of lncRNA-HEIH in tumor [J]. Journal of Practical Oncology, 2021, 35(1): 87-90.
[13]	GUO Yongdong, JIN Jing, LI Limin, HE Yutong. Progress in differentiation of non-protein-encoding RNA(DANCR)in common malignant tumors [J]. Journal of Practical Oncology, 2020, 34(1): 69-73.
[14]	WANG Jingxi, DONG Xiaoping, ZHANG Xue, HE Yutong. Research progress of MiR-26a in lung cancer [J]. Journal of Practical Oncology, 2019, 33(6): 561-565.
[15]	LI Susu, ZHOU Chunxiang. Two-way regulation of NKT cells on immune response to liver cancer [J]. Journal of Practical Oncology, 2019, 33(6): 540-543.

Advances in early biomarkers of anthracyclines related to cardiotoxicity

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments